NVCT

5 atoms · 跨 1 天 · 首见 2026-06-22 · 最近 2026-06-22

三色: 🟦 fact 5 · 🟥 take 0 · stance ▲2/▼0/◆3

来源: X 5

时态: fresh:5

标签: 好信源:5 · 好数字:3

事实 (fact) (5)

• 2026-06-22 · Haisco receives upfront and near-term payments up to $40M and milestones up to $1.421B plus royalties
  Haisco receives up to $40M upfront/near-term payments and up to $1.421B in milestones plus royalties.
  tags: 好数字·好信源 · → daily
  value: qty=up to $40M upfront/near-term, up to $1.421B milestones plus royalties
• 2026-06-22 · NXP100 in Phase 3 for PNH achieved 59.5% treatment-naive patients reaching Hb ≥12 g/dL without transfusion vs 8.3% for eculizumab
  NXP100 is late-stage in China for PNH, with 2 MAAs under NMPA review. In Phase 3, 59.5% of treatment-naive PNH patients reached Hb ≥12 g/dL without transfusion vs. 8.3% for eculizumab.
  tags: 好数字·好信源 · → daily
  value: qty=59.5% vs 8.3%
• 2026-06-22 · NXP200 showed >40% response in adult glioma in dose escalation
  NXP200 is a brain-penetrant BRAF inhibitor that showed >40% response in adult glioma in dose escalation.
  tags: 好数字·好信源 · → daily
  value: qty=>40% response rate
• 2026-06-22 · licensed ex-China rights to Haisco assets NXP100 and NXP200
  $NVCT licensed ex-China rights to two clinical-stage Haisco assets: NXP100 and NXP200.
  tags: 好信源 · → daily
• 2026-06-22 · deal subject to meeting financing conditions
  Deal is subject to NVCT meeting financing conditions.
  tags: 好信源 · → daily

时间轴 (近 20)

• 2026-06-22 · fact · licensed ex-China rights to Haisco assets NXP100 and NXP200 · → daily
• 2026-06-22 · fact · Haisco receives upfront and near-term payments up to $40M an · → daily
• 2026-06-22 · fact · NXP100 in Phase 3 for PNH achieved 59.5% treatment-naive pat · → daily
• 2026-06-22 · fact · NXP200 showed >40% response in adult glioma in dose escalati · → daily
• 2026-06-22 · fact · deal subject to meeting financing conditions · → daily

← 实体目录 · 系统日志